Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …